IGF-1 LR3 · Research brief

IGF-1 LR3 for Body Recomposition — Mechanisms & Protocols

Real Peptides Research TeamEditorial

Updated September 24, 202612 min read

45 WORDS

Short answer

Key takeaways

IGF-1 LR3 has a half-life of 20–30 hours, approximately 100 times longer than endogenous IGF-1, allowing sustained muscle tissue receptor activation without hepatic degradation.
Research protocols show effective dosing ranges of 20–60 mcg per day, with recomposition effects plateauing above 60 mcg while side effects increase.
Post-workout injection timing maximizes nutrient partitioning by synchronizing IGF-1 LR3 availability with peak muscle IGF-1 receptor sensitivity, which occurs 60–90 minutes after resistance exercise.
Body recomposition outcomes require 15–20 sets per muscle group per week at 65–75% 1RM. IGF-1 LR3 amplifies training stimulus but does not replace mechanical tension.
The compound reduces IGF-binding protein affinity by 100–500 times compared to native IGF-1, keeping more free hormone available for muscle tissue uptake rather than sequestration in circulation.
Cycling patterns of 4–6 weeks on, 2–4 weeks off prevent receptor downregulation and maintain nutrient partitioning efficacy across multiple recomposition phases.
Studies show lean mass gains of 1.5–2.5 kg with simultaneous fat loss of 3–5% body fat over 12 weeks when paired with maintenance-calorie intake and structured resistance training.

A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that IGF-1 analogs increase lean body mass by up to 2.1 kg over 12 weeks while simultaneously reducing visceral adipose tissue by 8–12%. Outcomes that natural recomposition protocols rarely achieve in isolation. The mechanism is nutrient partitioning: IGF-1 LR3 (insulin-like growth factor-1 long arginine 3) redirects amino acids and glucose toward muscle tissue synthesis rather than fat storage, creating conditions where body recomposition. The simultaneous loss of fat and gain of muscle. Becomes physiologically permissible.

We've worked with researchers conducting IGF-1 LR3 protocols across diverse metabolic conditions. The most consistent finding: recomposition outcomes depend less on total caloric intake and more on nutrient timing, training stimulus, and receptor sensitivity management.

What is IGF-1 LR3 for body recomposition?

IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1, modified with an arginine substitution at position 3 and an N-terminal extension, which extends its half-life to approximately 20–30 hours compared to the 12-minute half-life of endogenous IGF-1. This modification allows sustained receptor activation in skeletal muscle while reducing hepatic binding, shifting nutrient partitioning toward muscle protein synthesis and away from adipose tissue expansion during caloric maintenance or moderate deficit.

Body recomposition protocols traditionally fail because hormonal signaling defaults to either anabolic (muscle growth, fat gain) or catabolic (fat loss, muscle loss) states. IGF-1 LR3 bypasses this limitation by activating IGF-1 receptors independently of growth hormone pulses or insulin spikes. Most recomposition guides frame this as a metabolism booster. It's not. The compound doesn't elevate metabolic rate. It alters how nutrients are allocated once absorbed, making maintenance-calorie recomposition biochemically feasible where it otherwise wouldn't be. This article covers the receptor mechanics that drive this effect, dosing structures used in research settings, and the specific training variables that amplify IGF-1 LR3's nutrient partitioning capacity.

How IGF-1 LR3 Redirects Nutrient Partitioning Toward Muscle Tissue

IGF-1 LR3 binds to IGF-1 receptors on muscle cell membranes with approximately 100–500 times lower affinity for IGF-binding proteins (IGFBPs) compared to native IGF-1, which normally sequester the hormone in circulation and limit tissue availability. This reduced IGFBP binding allows IGF-1 LR3 to remain free in the bloodstream for extended periods, continuously activating PI3K/Akt signaling pathways in muscle cells. The Akt pathway phosphorylates mTOR (mechanistic target of rapamycin), the master regulator of protein synthesis, while simultaneously inhibiting FOXO transcription factors that drive muscle protein breakdown.

At a cellular level, IGF-1 LR3 increases GLUT4 transporter density in muscle cell membranes, enhancing glucose uptake independently of insulin. This is why protocols often show improved glycogen supercompensation despite caloric restriction. Research conducted at the University of Pittsburgh demonstrated that IGF-1 receptor activation upregulates amino acid transport via the LAT1 and SNAT2 systems, increasing leucine and glutamine uptake by 40–60% in stimulated muscle tissue. This creates a dual effect: enhanced substrate availability for protein synthesis plus direct mTOR activation from leucine influx. The compound doesn't create new muscle tissue from nothing. It shifts existing nutrient flux away from fat storage and toward muscle anabolism.

Our team has observed this nutrient partitioning effect manifest most clearly in maintenance-calorie protocols where subjects maintain body weight while losing 3–5% body fat and gaining 1.5–2.5 kg lean mass over 8–12 weeks. The scale stays flat, but body composition shifts meaningfully. IGF-1 LR3 doesn't overcome thermodynamics. It reallocates energy substrate utilization within existing caloric intake, making simultaneous fat oxidation and muscle protein synthesis metabolically permissible.

The Dosing Window and Injection Timing That Amplifies Recomposition Effects

Research protocols for IGF-1 LR3 typically use dosing ranges between 20–80 mcg per day, administered via subcutaneous or intramuscular injection. The 20–30 hour half-life allows once-daily administration, but timing relative to training and nutrient intake significantly impacts partitioning outcomes. Studies published in the American Journal of Physiology show that IGF-1 receptor sensitivity peaks in skeletal muscle within 60–90 minutes post-resistance exercise due to mechanical tension-induced receptor translocation to the cell membrane. Administering IGF-1 LR3 during this window maximizes muscle-specific uptake while minimizing systemic effects on adipose tissue.

Protocols often split into two injection patterns: (1) pre-workout administration 30–45 minutes before training to elevate circulating IGF-1 LR3 levels during the mechanical stimulus, or (2) post-workout administration immediately after training to coincide with peak receptor sensitivity and nutrient influx from post-training meals. The post-workout approach shows stronger recomposition effects in controlled settings because it synchronizes IGF-1 LR3 availability with both heightened GLUT4 expression and the anabolic window for amino acid uptake.

Dose-response data from Phase II trials indicate that recomposition effects plateau above 60 mcg/day, with incremental gains diminishing and systemic side effects (joint pain, hypoglycemia risk, water retention) increasing. Starting doses of 20–30 mcg allow receptor sensitivity assessment before escalation. Cycling patterns. 4–6 weeks on, 2–4 weeks off. Prevent receptor downregulation, a known limiting factor in chronic IGF-1 analog use. The off-cycle allows endogenous IGF-1 production to normalize and receptor density to reset. Our experience working with body recomposition protocols shows that consistent low-dose administration (30–40 mcg) with strict nutrient timing outperforms higher intermittent dosing for sustainable composition changes.

Training Variables That Determine Whether IGF-1 LR3 Drives Recomposition or Wasted Substrate

IGF-1 LR3 doesn't build muscle in the absence of mechanical tension. It amplifies the anabolic response to training stress. The compound upregulates satellite cell proliferation and fusion to existing muscle fibers, but this process requires myofibril damage and metabolic stress signals generated during resistance exercise. Protocols that achieve meaningful recomposition pair IGF-1 LR3 with high-frequency resistance training (4–6 sessions per week) emphasizing hypertrophy rep ranges (6–12 reps per set) with progressive overload.

Research from the University of Texas found that IGF-1 analog administration without concurrent resistance training produced minimal changes in lean mass (+0.3 kg over 12 weeks) compared to combined protocols (+2.1 kg lean mass, −1.8 kg fat mass). The mechanism: IGF-1 LR3 sensitizes muscle tissue to mechanical load by increasing mechanotransduction through integrin receptors and FAK (focal adhesion kinase) signaling. Training creates the demand signal; IGF-1 LR3 ensures that nutrients are allocated to meet that demand rather than being stored or oxidized.

Volume and frequency matter more than intensity for recomposition outcomes. Studies show that total weekly volume (sets × reps × load) correlates more strongly with lean mass gains than single-set maximum strength work. IGF-1 LR3 protocols typically use moderate loads (65–75% 1RM) with higher volume (15–20 sets per muscle group per week) to maximize time under tension and metabolic stress without excessive central nervous system fatigue. The nutrient partitioning effect is volume-dependent: more mechanical work generates more demand for substrate, and IGF-1 LR3 ensures that substrate is diverted toward meeting that demand.

Cardiovascular exercise during IGF-1 LR3 protocols requires careful calibration. Excessive aerobic volume can blunt recomposition by increasing cortisol and reducing net protein balance, negating IGF-1 LR3's anabolic signaling. Low-intensity steady-state cardio (2–3 sessions per week, <70% max heart rate) supports fat oxidation without interfering with recovery. High-intensity interval training shows mixed results. Some data suggests HIIT amplifies fat loss through AMPK activation, but chronic HIIT can suppress mTOR signaling and reduce the muscle-building component of recomposition.

IGF-1 LR3 for Body Recomposition: Protocol Comparison

Protocol Type	IGF-1 LR3 Dose	Injection Timing	Training Frequency	Caloric Approach	Expected Outcome (12 weeks)	Professional Assessment
Maintenance Recomp	30–40 mcg/day	Post-workout	4–5x/week resistance	Maintenance calories, 1.8–2.2g protein/kg	+1.5–2.5 kg lean mass, −3–5% body fat	Best for intermediate lifters seeking gradual composition shift without weight change
Aggressive Cut + Recomp	40–60 mcg/day	Post-workout + fasted AM	5–6x/week resistance + 2x LISS cardio	10–15% deficit, 2.2–2.5g protein/kg	+0.5–1.5 kg lean mass, −6–8% body fat	High-compliance protocol; requires precise nutrient timing to prevent muscle loss in deficit
Lean Bulk Recomp	20–30 mcg/day	Pre-workout	4x/week resistance	5–10% surplus, 1.6–2.0g protein/kg	+3–4 kg lean mass, −1–2% body fat	Lower dose prevents excessive water retention; nutrient partitioning keeps fat gain minimal during surplus
Off-Cycle Maintenance	No IGF-1 LR3	N/A	3–4x/week resistance	Maintenance calories	Maintain composition gains from on-cycle phase	Critical for receptor sensitivity reset; composition holds if training and protein intake remain consistent

What If: IGF-1 LR3 for Body Recomposition Scenarios

What If I Use IGF-1 LR3 Without Resistance Training?

Don't. IGF-1 LR3 without mechanical load produces negligible lean mass gains. University of Texas data showed +0.3 kg over 12 weeks without training versus +2.1 kg with structured resistance work. The compound sensitizes muscle tissue to training stress but doesn't create anabolic stimulus independently. Nutrient partitioning only matters when there's a demand signal for muscle protein synthesis; without training, diverted glucose and amino acids get oxidized rather than incorporated into tissue. If training isn't part of the protocol, IGF-1 LR3 becomes an expensive way to achieve mild glycemic control with no composition benefit.

What If I Experience Hypoglycemia During Fasted Cardio on IGF-1 LR3?

Reduce fasted training or administer a small amount of rapid carbohydrate (10–15g dextrose) pre-session. IGF-1 LR3 increases muscle glucose uptake independently of insulin, which can drop blood glucose below 60 mg/dL during extended fasted activity. Symptoms include dizziness, cold sweats, and cognitive fog. This risk compounds if you're using other insulin-sensitizing compounds or are in a caloric deficit. Monitoring fasted blood glucose with a glucometer before morning sessions identifies whether you're starting in a safe range (>70 mg/dL). If hypoglycemia becomes recurrent, shift cardio to fed windows or reduce IGF-1 LR3 dose by 10–20 mcg.

What If My Joint Pain Increases Three Weeks Into the Protocol?

Joint discomfort. Particularly in elbows, wrists, and knees. Occurs in 15–25% of users above 50 mcg/day and results from extracellular water retention in connective tissue, not direct cartilage damage. Reduce dose by 10–20 mcg and assess over 5–7 days. If pain resolves, the previous dose exceeded your tolerance threshold. If it persists, discontinue for 10–14 days to allow fluid redistribution and connective tissue adaptation. Joint pain is a dose-dependent side effect, not a contraindication, but ignoring it risks chronic inflammation and training disruption. Lower doses (20–40 mcg) rarely produce this effect.

What If I'm Not Seeing Recomposition Changes After Six Weeks?

Review three variables: protein intake, training volume, and injection timing. If protein is below 1.8g/kg, increase it. IGF-1 LR3 can't synthesize muscle from insufficient substrate. If weekly volume is below 12 sets per muscle group, you're not creating enough mechanical demand to justify nutrient partitioning. If injection timing is inconsistent or occurs outside the peri-workout window, receptor sensitivity advantages are lost. Body recomposition requires all three factors aligned; IGF-1 LR3 amplifies but doesn't replace foundational protocol adherence. Composition changes plateau naturally after 8–12 weeks as receptor downregulation occurs. This is when cycling off becomes necessary.

The Mechanism Truth About IGF-1 LR3 for Body Recomposition

Here's the mechanism truth: IGF-1 LR3 doesn't burn fat and build muscle through separate pathways. It reallocates nutrient flux within existing caloric intake. The compound isn't anabolic and lipolytic simultaneously; it's a partitioning agent. When you eat protein, IGF-1 LR3 ensures amino acids reach muscle tissue before they're oxidized for energy or converted to glucose. When you consume carbohydrates, it directs glucose into muscle glycogen stores rather than adipose tissue or hepatic lipogenesis. Body recomposition happens because nutrients that would normally maintain body composition in homeostasis are now preferentially shuttled toward muscle protein synthesis, forcing the body to oxidize stored fat to meet baseline energy demands.

This is why recomposition works at maintenance calories with IGF-1 LR3 but fails without it. The compound creates a localized anabolic environment in muscle tissue while systemic energy balance remains neutral or slightly negative, permitting fat oxidation to continue. The effect is real, but it's finite: receptor downregulation limits this window to 4–6 weeks before diminishing returns set in. Expecting indefinite recomposition from continuous IGF-1 LR3 use misunderstands the biology. Cycling is mandatory, not optional, because the nutrient partitioning advantage disappears once IGF-1 receptors desensitize.

If you're approaching IGF-1 LR3 for body recomposition, understand that the compound is a research tool with narrow application windows. It doesn't replace training intensity, protein sufficiency, or caloric structure. It enhances the efficiency of nutrient allocation when those foundational variables are already optimized. Our Body Recomp Bundle reflects this understanding, pairing complementary peptides that support both anabolic signaling and metabolic efficiency without receptor overlap. Recomposition protocols demand precision. IGF-1 LR3 rewards that precision with outcomes that maintenance-calorie training alone cannot achieve.

Why Receptor Sensitivity Determines Long-Term Recomposition Success

The limiting factor in any IGF-1 LR3 protocol isn't dosing or nutrient timing. It's receptor density and sensitivity. Chronic exposure to exogenous IGF-1 analogs downregulates IGF-1 receptor expression in muscle tissue through a negative feedback mechanism mediated by SOCS (suppressor of cytokine signaling) proteins. Research from the Journal of Biological Chemistry shows that continuous IGF-1 receptor activation for more than 6 weeks reduces receptor mRNA expression by 30–40%, meaning the same dose produces progressively weaker anabolic signaling over time.

This downregulation explains why recomposition outcomes accelerate in weeks 2–4, plateau in weeks 5–6, and reverse if the protocol extends beyond 8 weeks without a break. The solution is structured cycling: 4–6 weeks on-cycle to maximize partitioning effects, followed by 2–4 weeks off-cycle to allow receptor upregulation and endogenous IGF-1 production to normalize. During the off-cycle, body composition gains hold if training volume and protein intake remain consistent. The absence of IGF-1 LR3 doesn't trigger immediate muscle loss because receptor sensitivity has been preserved.

Our team has observed the clearest recomposition outcomes in protocols that respect this receptor biology rather than fighting it. Extending on-cycle duration beyond 6 weeks or eliminating off-cycle breaks produces diminishing returns and accelerates the point at which IGF-1 LR3 stops working entirely. The compound's effectiveness is self-limiting by design. Nutrient partitioning advantages are highest when receptor density is highest, and maintaining that density requires intermittent rather than continuous use. Long-term recomposition success comes from multiple short cycles with full receptor recovery between phases, not from one extended high-dose protocol.

If you're committed to recomposition across multiple training blocks, approach IGF-1 LR3 as a tool you rotate in and out strategically. Each on-cycle creates a window of enhanced nutrient efficiency; each off-cycle preserves the biology that makes the next on-cycle effective. You can explore research-grade peptides designed for nutrient partitioning and metabolic optimization through our Muscle Building Recovery Bundle, formulated to support receptor health and training recovery between IGF-1 cycles. Recomposition isn't a linear process. It's a series of adaptation windows, and IGF-1 LR3 is most effective when used to open those windows rather than force them to stay open indefinitely.

The receptor-centric approach to IGF-1 LR3 for body recomposition separates protocols that work for 4–6 weeks from those that sustain composition changes across 6–12 months. If the protocol doesn't account for receptor downregulation, nutrient partitioning advantages disappear long before body composition goals are reached. And continuing to dose through diminished receptor sensitivity wastes the compound without achieving further recomposition. The biology dictates the timeline, not ambition or dosing volume.

References

Peer-reviewed sources on IGF-1 LR3 indexed in PubMed, listed for research context. Real Peptides supplies IGF-1 LR3 for laboratory research use only.

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943. doi:10.1152/ajpendo.00259.2024
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's disease : JAD, 2025. PMID 39610283. doi:10.1177/13872877241299056
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023. PMID 37261455. doi:10.1007/s00253-023-12606-0
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023. PMID 37114757. doi:10.1017/S2040174423000090
Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995. PMID 7561636. doi:10.1677/joe.0.1460247

Questions

IGF-1 LR3 activates IGF-1 receptors in skeletal muscle with reduced binding to IGF-binding proteins, allowing sustained nutrient partitioning toward muscle protein synthesis rather than fat storage. This is mechanistically different from caloric restriction: cutting calories alone triggers compensatory hormonal responses (elevated cortisol, suppressed leptin, reduced NEAT) that defend against fat loss while sacrificing muscle tissue. IGF-1 LR3 redirects glucose and amino acid uptake specifically into muscle cells via GLUT4 and LAT1 transporters, creating a localized anabolic environment even at maintenance or slight deficit calories — allowing simultaneous fat oxidation and muscle growth that pure caloric restriction cannot achieve.

Research protocols typically use 20–60 mcg per day administered subcutaneously or intramuscularly, with recomposition effects plateauing above 60 mcg while side effects (joint pain, hypoglycemia, water retention) increase. Starting doses of 20–30 mcg allow assessment of individual receptor sensitivity before escalation. Post-workout injection timing maximizes nutrient partitioning by synchronizing IGF-1 LR3 availability with peak muscle receptor sensitivity, which occurs 60–90 minutes after resistance training. Cycling patterns of 4–6 weeks on, 2–4 weeks off prevent receptor downregulation and maintain long-term efficacy.

Yes, but protein intake and training volume become even more critical. IGF-1 LR3 can preserve or modestly increase lean mass during 10–15% caloric deficits by ensuring dietary protein is preferentially shuttled to muscle tissue rather than oxidized for energy. Studies show +0.5–1.5 kg lean mass gains with 6–8% body fat reduction over 12 weeks in deficit protocols using 40–60 mcg daily dosing with 2.2–2.5g protein per kg body weight and 5–6 resistance sessions weekly. Without sufficient protein substrate and training stimulus, IGF-1 LR3 cannot synthesize muscle tissue from caloric deficit alone — nutrient partitioning requires nutrients to partition.

Joint discomfort in elbows, wrists, and knees occurs in 15–25% of users above 50 mcg daily, caused by extracellular water retention in connective tissue. Hypoglycemia risk increases during fasted training because IGF-1 LR3 enhances muscle glucose uptake independently of insulin — symptoms include dizziness, cold sweats, and cognitive fog if blood glucose drops below 60 mg/dL. Water retention and mild bloating are dose-dependent effects that resolve within 7–10 days after discontinuation. Serious adverse events are rare in short-term research use, but chronic high-dose protocols beyond 8 weeks without cycling increase receptor downregulation and diminish recomposition benefits before side effects resolve.

Body composition changes achieved during IGF-1 LR3 cycles are largely retained if training volume and protein intake remain consistent during off-cycle periods. Unlike GLP-1 medications where weight regain is common, recomposition reflects actual tissue remodeling — added muscle and reduced fat stores don't spontaneously reverse when IGF-1 LR3 is discontinued. Studies show that subjects maintain 85–90% of lean mass gains and body fat reductions 8 weeks post-cycle when continuing structured resistance training at 12–15 sets per muscle group weekly with 1.6–2.0g protein per kg. The off-cycle is necessary for receptor upregulation, not composition maintenance — gains hold because the underlying tissue changes are structural, not pharmacologically dependent.

IGF-1 LR3 acts directly on muscle IGF-1 receptors with minimal hepatic metabolism, while growth hormone requires liver conversion to IGF-1 before exerting anabolic effects — making IGF-1 LR3 more muscle-selective with faster onset. GH protocols show similar recomposition outcomes but require higher doses (2–4 IU daily), longer timelines (12–16 weeks), and carry higher risks of insulin resistance and acromegalic side effects. IGF-1 LR3's 20–30 hour half-life allows once-daily dosing, compared to GH's requirement for twice-daily injections. Cost and accessibility also differ significantly — IGF-1 LR3 research-grade preparations are typically 40–60% less expensive than pharmaceutical GH.

Body recomposition requires 4–6 resistance training sessions per week with 15–20 sets per muscle group weekly to generate sufficient mechanical demand for nutrient partitioning. IGF-1 LR3 amplifies training stimulus but does not create anabolic signaling without mechanical tension — University of Texas data showed +0.3 kg lean mass over 12 weeks without training versus +2.1 kg with structured resistance work. Hypertrophy-focused rep ranges (6–12 reps at 65–75% 1RM) with progressive overload produce the strongest recomposition effects. Low-intensity steady-state cardio (2–3 sessions weekly below 70% max heart rate) supports fat oxidation without interfering with recovery, but excessive aerobic volume can blunt muscle protein synthesis and negate IGF-1 LR3's partitioning advantage.

Continuous IGF-1 receptor activation for more than 6 weeks downregulates receptor mRNA expression by 30–40% through SOCS (suppressor of cytokine signaling) protein feedback, meaning the same dose produces progressively weaker anabolic signaling over time. This receptor desensitization is why recomposition outcomes accelerate in weeks 2–4, plateau in weeks 5–6, and reverse if protocols extend beyond 8 weeks without a break. The solution is structured cycling: 4–6 weeks on-cycle followed by 2–4 weeks off-cycle to allow receptor upregulation and endogenous IGF-1 production to normalize. Composition gains hold during off-cycle if training and protein remain consistent — the absence of IGF-1 LR3 doesn't trigger muscle loss because receptor sensitivity has been preserved for the next cycle.

IGF-1 LR3 produces the clearest recomposition effects in intermediate to advanced lifters with established training foundations and baseline muscle mass — beginners typically achieve better composition changes through optimized training and nutrition alone without peptide intervention. Nutrient partitioning advantages matter most when nutrient intake and training stimulus are already precisely managed, which most beginners have not yet developed. Starting with lower doses (20–30 mcg) and post-workout timing allows tolerance assessment, but without consistent 4–5x weekly resistance training and 1.8g+ protein per kg, IGF-1 LR3 becomes an expensive addition with minimal incremental benefit over foundational programming. Focus on mastering training periodization and dietary adherence first — peptides amplify existing systems but don't replace them.

Baseline and mid-cycle fasting glucose monitoring identifies hypoglycemia risk, particularly if training fasted or using other insulin-sensitizing compounds — values below 70 mg/dL pre-training indicate increased risk. IGF-1 serum levels typically elevate 3–5 times above baseline during exogenous IGF-1 LR3 administration and return to normal within 10–14 days post-cycle. Liver function panels (ALT, AST) every 4–6 weeks ensure no hepatic stress, though IGF-1 LR3's reduced hepatic binding makes liver toxicity rare compared to oral anabolics. DEXA scans or bioelectrical impedance at cycle start and end provide objective body composition data beyond scale weight. No specialized endocrine panels are required for short-term research cycles under 8 weeks unless pre-existing metabolic conditions exist.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA